US 11,987,646 B2
Immunomodulatory peptides
Gabriel M. Gutierrez, Reston, VA (US); James Pannucci, Reston, VA (US); Michael Ryan Weil, Reston, VA (US); Timothy W. Phares, Reston, VA (US); Vinayaka Kotraiah, Reston, VA (US); Cecille D. Browne, Reston, VA (US); and Peter J. Buontempo, Reston, VA (US)
Assigned to Leidos, Inc., Reston, VA (US)
Filed by Leidos, Inc., Reston, VA (US)
Filed on Oct. 8, 2021, as Appl. No. 17/497,069.
Claims priority of provisional application 63/090,324, filed on Oct. 12, 2020.
Prior Publication US 2022/0112243 A1, Apr. 14, 2022
Int. Cl. A61P 35/00 (2006.01); A61K 38/10 (2006.01); A61K 45/06 (2006.01); C07K 7/08 (2006.01)
CPC C07K 7/08 (2013.01) [A61K 38/10 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 17 Claims
 
1. A peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.